

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

“DOCETAXEL FOR INJECTION (ALBUMIN-BOUND)” OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Docetaxel for Injection (albumin-bound)” (the “**Product**”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Company, has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product applies innovative technology to encapsulate docetaxel into human serum albumin, and is planned to develop for solid tumor indication. Compared with docetaxel injection, the Product has the following advantages: (1) safety: it enhances safety and patient compliance by rapid administration of concentrated dosage without hormone pre-treatment; (2) efficacy: it demonstrates significant efficacy in multiple tumor models in pre-clinical studies, and allows higher dosage clinically to further enhance efficacy. The Product is expected to demonstrate good anti-tumor efficacy in the clinical studies.

The Product is a class 2 chemical drug and currently there is no product of the same type available in the global market. The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 19 May 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

** For identification purpose only*